Transparency notification Wellington

Brussels (Belgium), 23 November 2023 – 20:00 (CET) – Regulated information 

1.  Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 20 November 2023. 

Wellington Management Group LLP has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and it has crossed the 7.5% threshold downwards, on 17 November 2023.

On 17 November 2023, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 14 548 260 UCB shares with voting rights, representing 7.48% of the total number of shares issued by the company (194 505 658), versus 7.80% (15 166 845 UCB shares) in the previous notification dated 16 May 2022.

2.  Content of the notification

• Reason for the notification: Acquisition or disposal of voting securities or voting rights. 
• Notification by: A parent undertaking or a controlling person.
• Persons subject to the notification requirement: 

• Date on which the threshold is crossed: 17 November 2023. 
• Threshold crossed (in %): 7.5%.
• Denominator: 194 505 658.

• Notified details:

•  Chain of controlled undertakings through which the holding is effectively held:

• Additional information: Wellington Management Company LLP, Wellington Management International Ltd and Wellington Management Europe GmbH are investment management companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.

3.  Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news